Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc.APUS · Entity 8263 | Director | November 11, 2025 | November 13, 2025 |
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | General Counsel | January 02, 2020 | January 07, 2020 |
| Seer, Inc.SEER · Entity 6717 | CHIEF LEGAL OFFICER | February 06, 2024 | February 23, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apimeds Pharmaceuticals US, Inc.
Report date November 11, 2025 · Filed November 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2035-11-11 | Direct | 10,000 |
Reported balance
After 2025-11-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-11 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan.
Cartesian Therapeutics, Inc.
Report date January 02, 2020 · Filed January 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2030-01-01 | Direct | 140,000 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 140,000 · Balance 140,000 F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Seer, Inc.
Report date February 06, 2024 · Filed February 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 273,142 |
Ending reported balance
After 2024-02-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-06 · Grant · Acquired 123,153 · Balance 285,826 F1: The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on February 15, 2025. Row 2 · 2024-02-22 · Sale · Disposed 12,684 · Balance 273,142 F2: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of RSUs. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-02-06 | Direct | 79,729 |
Reported balance
After 2024-02-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-06 · Grant · Acquired 79,729 · Balance 79,729 F3: One-fourth of the shares subject to the option vest on February 6, 2025 and 1/48th of the shares vest monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-02-06 | Direct | 140,000 |
Reported balance
After 2024-02-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-06 · Grant · Acquired 140,000 · Balance 140,000 F4: The option is subject to vesting requirements based upon achievement of specified performance-based criteria (the "Stock Price Hurdle") which requires that the Issuer achieve a stock price equal to or greater than 200% of the option exercise price during the period beginning on the grant date and ending on February 6, 2031 (the "Performance Period"). If the Stock Price Hurdle is achieved within the Performance Period, then one-fourth of the shares subject to the option vest on the date that achievement of the Stock Price Hurdle is certified and the remaining shares vest annually thereafter in three equal installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on February 15, 2025.
F2: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of RSUs.
F3: One-fourth of the shares subject to the option vest on February 6, 2025 and 1/48th of the shares vest monthly thereafter.
F4: The option is subject to vesting requirements based upon achievement of specified performance-based criteria (the "Stock Price Hurdle") which requires that the Issuer achieve a stock price equal to or greater than 200% of the option exercise price during the period beginning on the grant date and ending on February 6, 2031 (the "Performance Period"). If the Stock Price Hurdle is achieved within the Performance Period, then one-fourth of the shares subject to the option vest on the date that achievement of the Stock Price Hurdle is certified and the remaining shares vest annually thereafter in three equal installments.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 6,085 · Balance 0 F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
F2: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2025 Filed Nov 13, 2025 23:28 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001679971-25-000008 · primary_doc.xml · derivative · entry 1 Kogan Elona · CIK 0001679971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.01 per share · 10,000 shares Expires 2035-11-11 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's employment continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the Company's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full vest upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| October 15, 2025 Filed Oct 24, 2025 20:35 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001679971-25-000007 · primary_doc.xml · derivative · entry 1 Kogan Elona · CIK 0001679971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock, par value $0.01 per share · 3,000 shares Expires 2035-10-15 F1 · derivative.exercise_date: The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the "Plan") to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:18 UTC | Apimeds Pharmaceuticals US, Inc. APUS · Entity 8263 | GrantStock Option (right to buy) · Derivative | 5,780 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001474506-25-000103 · primary_doc.xml · derivative · entry 1 Kogan Elona · CIK 0001679971 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,780 Underlying: Common Stock, par value $0.01 per share · 5,780 shares Expires 2035-05-16 F1 · derivative.exercise_date: The option will vest in full and become exercisable on 05/16/2026. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 22:32 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 12,684 | $1.58 | $20,024.23 |
DisclosureSEC source: 0001415889-24-005096 · form4-02232024_100220.xml · nonDerivative · entry 2 Kogan Elona · CIK 0001679971 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,142 F2 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of RSUs. Read SEC document |
| February 06, 2024 Filed Feb 23, 2024 22:32 UTC | Seer, Inc. SEER · Entity 6717 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-24-005096 · form4-02232024_100220.xml · derivative · entry 4 Kogan Elona · CIK 0001679971 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Class A Common Stock · 140,000 shares Expires 2034-02-06 F4 · derivative.exercise_date: The option is subject to vesting requirements based upon achievement of specified performance-based criteria (the "Stock Price Hurdle") which requires that the Issuer achieve a stock price equal to or greater than 200% of the option exercise price during the period beginning on the grant date and ending on February 6, 2031 (the "Performance Period"). If the Stock Price Hurdle is achieved within the Performance Period, then one-fourth of the shares subject to the option vest on the date that achievement of the Stock Price Hurdle is certified and the remaining shares vest annually thereafter in three equal installments. Read SEC document |
| February 06, 2024 Filed Feb 23, 2024 22:32 UTC | Seer, Inc. SEER · Entity 6717 | GrantEmployee Stock Option (right to buy) · Derivative | 79,729 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-24-005096 · form4-02232024_100220.xml · derivative · entry 3 Kogan Elona · CIK 0001679971 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,729 Underlying: Class A Common Stock · 79,729 shares Expires 2034-02-06 F3 · derivative.exercise_date: One-fourth of the shares subject to the option vest on February 6, 2025 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| February 06, 2024 Filed Feb 23, 2024 22:32 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 123,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005096 · form4-02232024_100220.xml · nonDerivative · entry 1 Kogan Elona · CIK 0001679971 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,826 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on February 15, 2025. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:43 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 8,182 | $1.70 | $13,869.31 |
DisclosureSEC source: 0001209191-23-057620 · doc4.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,673 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · balance_after: Includes 1,168 shares and 3,100 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 15, 2023 and November 15, 2023, respectively. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 00:09 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 5,951 | $4.13 | $24,603.22 |
DisclosureSEC source: 0001209191-23-011919 · doc4.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,587 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · balance_after: Includes 1,168 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 15, 2022. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:53 UTC | Seer, Inc. SEER · Entity 6717 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-23-010927 · doc4.xml · derivative · entry 2 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Class A Common Stock · 140,000 shares Expires 2033-02-15 F2 · derivative.exercise_date: The option is subject to vesting requirements based upon achievement of specified performance-based criteria (the "Stock Price Hurdle") which requires that the Issuer achieve a stock price equal to or greater than 150% of the option exercise price during the period beginning on the grant date and ending on February 15, 2030 (the "Performance Period"). If the Stock Price Hurdle is achieved within the Performance Period, then one fourth of the shares subject to the option vest on the date that achievement of the Stock Price Hurdle is certified and the remaining shares vest annually thereafter in three equal installments. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:53 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010927 · doc4.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,370 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on February 15, 2024. Read SEC document |
| June 08, 2022 Filed Jun 11, 2022 00:17 UTC | Seer, Inc. SEER · Entity 6717 | SaleClass A Common Stock | 8,185 | $8.91 | $72,923.44 |
DisclosureSEC source: 0001209191-22-036155 · doc4.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,370 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 827 shares of Class A Common Stock acquired under the Issuer's employee stock purchase plan on November 15, 2021. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:13 UTC | Seer, Inc. SEER · Entity 6717 | GrantEmployee Stock Option (right to buy) · Derivative | 124,000 | $0.00 Strike: $16.61 | $0.00 |
DisclosureSEC source: 0001209191-22-008619 · doc4.xml · derivative · entry 2 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Class A Common Stock · 124,000 shares Expires 2032-02-08 F2 · derivative.exercise_date: One-fourth of the shares subject to the option vest on February 8, 2023 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| February 08, 2022 Filed Feb 11, 2022 00:13 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008619 · doc4.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,728 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on February 15, 2023. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 00:27 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 46,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-017232 · wf-form4_160747363396161.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,728 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, pursuant to which 50% vest on June 8, 2022 and the remaining shares vest on December 8, 2023. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:08 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000013 · wf-form4_157835927771425.xml · derivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 20:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 82,872 | $1.81 | $149,998.32 |
DisclosureSEC source: 0001453687-19-000123 · wf-form4_156633311554335.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,872 F1 · balance_after: Total shares reported includes 50,000 shares underlying unvested restricted stock units. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:17 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001679971-19-000005 · wf-form4_155371785653312.xml · derivative · entry 2 Kogan Elona Esq. · CIK 0001679971 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-03-24 F2 · derivative.exercise_date: This option vests as to 25% on March 20, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2019 Filed Mar 27, 2019 20:17 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001679971-19-000005 · wf-form4_155371785653312.xml · nonDerivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · kind: Represents shares underlying Restricted Stock Unit awards, which vest, and the underlying shares become issuable, upon achievement of specified performance goals. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:14 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerRestricted Stock Units · Derivative | 6,085 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000048 · wf-form4_148727245801390.xml · derivative · entry 3 Kogan Elona Esq. · CIK 0001679971 · Sr. V. P. - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,085 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder shall be converted into the right to receive an amount in cash equal to $24.00 for each Share underlying the RSUs (the aggregate amount, the "RSU Payment"). Subject to the terms of the award agreement, the RSU Payment will generally be payable (without any crediting of interest for the period from the consummation of the Offer through the date of payment) in three annual installments with each such installment paid on the date that the RSUs corresponding to such installment would have otherwise vested in accordance with the terms of the award, less any required withholding taxes. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:14 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000048 · wf-form4_148727245801390.xml · derivative · entry 2 Kogan Elona Esq. · CIK 0001679971 · Sr. V. P. - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a right to receive one Share. Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Offer automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document |
| February 16, 2017 Filed Feb 16, 2017 14:14 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000884731-17-000048 · wf-form4_148727245801390.xml · derivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · Sr. V. P. - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F1 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 16:59 UTC | ARIAD PHARMACEUTICALS INC ARIA · Entity 134569 | GrantRestricted Stock Units · Derivative | 6,085 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000884731-17-000031 · wf-form4_148650473314100.xml · derivative · entry 1 Kogan Elona Esq. · CIK 0001679971 · Sr. V. P. - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,085 Underlying: Common Stock · 6,085 shares Expires not disclosed F1 · derivative.exercise_date: The Restricted Stock Units ("RSUs") vest as to approximately one-third of the shares underlying the RSUs on each anniversary of the grant date; provided, however, that, subject to and effective upon the consummation of the transactions contemplated by that certain Agreement and Plan of Merger between ARIAD, Takeda Pharmaceutical Company Limited, and Kiku Merger Co., Inc., dated January 8, 2017, the RSUs shall be converted into the right to receive a cash amount equal to $24.00 for each share of common stock underlying the RSUs, payable in three annual installments on each anniversary of the grant date, subject to the terms of the award. F2 · derivative.expiration_date: N/A Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.